Evaluation of the Effects of Cultured Bone Marrow Mesenchymal Stem Cell Infusion on Hepatocarcinogenesis in Hepatocarcinogenic Mice With Liver Cirrhosis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Inc Country of Publication: United States NLM ID: 0243532 Publication Model: Print Cited Medium: Internet ISSN: 1873-2623 (Electronic) Linking ISSN: 00411345 NLM ISO Abbreviation: Transplant Proc Subsets: MEDLINE
    • Publication Information:
      Publication: New York, N.Y. : Elsevier Science Inc.
      Original Publication: New York Stratton.
    • Subject Terms:
      Bone Marrow Transplantation/*methods ; Liver Cirrhosis/*surgery ; Liver Neoplasms, Experimental/*prevention & control ; Mesenchymal Stem Cell Transplantation/*methods ; Mesenchymal Stem Cells/*cytology; Animals ; Carcinogenesis ; Cells, Cultured ; Liver Cirrhosis/complications ; Liver Cirrhosis/pathology ; Liver Neoplasms, Experimental/etiology ; Liver Neoplasms, Experimental/pathology ; Male ; Mice ; Mice, Inbred C57BL
    • Abstract:
      Objectives: Liver transplantation remains the only curative therapy for decompensated liver cirrhosis. However, it has several limitations, and not all patients can receive liver transplants. Therefore, liver regenerative therapy without liver transplantation is considered necessary. In this study, we attempted minimally invasive liver regenerative therapy by peripheral vein infusion of bone marrow-derived mesenchymal stem cells (BMSCs) cultured from a small amount of autologous bone marrow fluid and evaluated the effects of BMSCs on hepatocarcinogenesis in a mouse model.
      Methods: C57BL/6 male mice were injected intraperitoneally with N-nitrosodiethylamine once at 2 weeks of age, followed by carbon tetrachloride twice a week from 6 weeks of age onwards, to create a mouse model of highly oncogenic liver cirrhosis. From 10 weeks of age, mouse isogenic green fluorescent protein-positive BMSCs (1.0 × 10 6 /body weight) were infused once every 2 weeks, for a total of 5 times, and the effects of frequent BMSC infusion on hepatocarcinogenesis were evaluated.
      Results: In the histologic evaluation, no significant differences were observed between the controls and BMSC-administered mice in terms of incidence rate, number, or average size of foci and tumors. However, significant suppression of fibrosis and liver injury was confirmed in the group that received BMSC infusions.
      Discussion: Considering that BMSC infusion did not promote carcinogenesis, even in the state of highly oncogenic liver cirrhosis, autologous BMSC infusion might be a safe and effective therapy for human decompensated liver cirrhosis.
      (Copyright © 2019 Elsevier Inc. All rights reserved.)
    • Publication Date:
      Date Created: 20190414 Date Completed: 20190528 Latest Revision: 20190528
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/j.transproceed.2019.03.011
    • Accession Number:
      30979485